Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy

Bortezomib and dexamethasone demonstrate efficacy benefit in key subgroups vs daratumumab, bortezomib, and dexamethasone in RRMM

HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC

CAR-T, bispecifics or ADCs in late-stage RRMM

Complementing clinical trials: Investigating the value of real world evidence with insights from TE NDMM

Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET/CT and whole-body diffusion weighted MRI

Melflufen and dexamethasone versus pomalidomide and dexamethasone in relapsed refractory multiple myeloma

Blood tumour mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer

Avelumab plus platinum-based chemotherapy may show some efficacy in patients with extensive-stage small cell lung cancer

Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer

Comment: EBCC 2024 highlights

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours